Ratings agency Standard & Poor's is making changes to one of its Australian indexes. Western Australia-based biotechnology company, Chemeq, is being promoted from the S&P/ASX 300 index to the S&P/ASX 200 index after the end of June 2003. Though Chemeq has yet to produce the first commercial batch of its veterinary drug, its share price has risen from under $A3 to $A7.30 in six months. Steven Piotrowski of Hartleys says Chemeq's share price has been driven by sentiment from biomez news
CMQ Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held